Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Anlotinib Combined With Pemetrexed And Carboplatin Followed by Maintenance Therapy With Anlotinib Plus Pemetrexed as the First-line Treatment in Patients With Advanced Nonsquamous NSCLC

NCT03790228 is registered in ClinicalTrials.gov with Henan Cancer Hospital as lead sponsor.

NCT NCT03790228
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03790228 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Anlotinib Combined With Pemetrexed And Carboplatin Followed by Maintenance Therapy With Anlotinib Plus Pemetrexed as the First-line Treatment in Patients With Advanced Nonsquamous NSCLC
Lead sponsor
Henan Cancer Hospital
Phase
Phase 1
Overall status
Unknown status
Start date
March 22, 2019
Completion date
August 31, 2021
Enrollment
43 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-squamous cell non-small cell lung cancer